Premium
Impact of recipient ABH secretor status on outcome in minor ABO ‐incompatible hematopoietic stem cell transplantation
Author(s) -
Holbro Andreas,
Stern Martin,
Infanti Laura,
O'Meara Alix,
Drexler Beatrice,
Frey Beat M.,
Tiercy JeanMarie,
Passweg Jakob R.,
Gassner Christoph,
Buser Andreas,
Sigle JoergPeter
Publication year - 2015
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.12768
Subject(s) - abo blood group system , hematopoietic stem cell transplantation , immunology , medicine , transplantation , cumulative incidence , incidence (geometry) , gastroenterology , physics , optics
Background The impact of ABO incompatibility on hematopoietic stem cell transplantation ( HSCT ) outcome is controversial. As ABH substances are expressed on tissues and secreted in body fluids, they could drive an immune response in minor ABO ‐incompatible HSCT . The aim of the study was to investigate the prognostic role of the recipients' ABH secretor status. Study Design and Methods Patients who underwent minor ABO ‐incompatible HSCT were included. Secretor status was determined either serologically or by molecular genetics. Results Between M arch 1996 and J une 2012, a total of 176 patients received minor ABO ‐incompatible HSCT and 150 (85%) were secretors. Incidence and severity of acute graft‐versus‐host disease ( GVHD ) and chronic GVHD did not differ between secretors and nonsecretors (cumulative incidences ± standard errors: acute GVHD on D ay 100, 41 ± 11 and 46 ± 5%, p = 0.59; chronic GVHD at 2 years, 52 ± 13 and 56 ± 5%, p = 0.62, for secretors and nonsecretors, respectively). Additionally, nonrelapse mortality ( NRM ) and overall survival ( OS ) were similar in the two groups (2‐year NRM , 27 ± 9 and 23 ± 3%, p = 0.45; 4‐year OS , 64 ± 10 and 55 ± 4%, p = 0.28, for secretors and nonsecretors, respectively). Conclusion The recipients' ABH secretor status in minor ABO ‐incompatible HSCT has no prognostic impact on major transplant outcomes.